Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Galidesivir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Galidesivir SCHEMBL17117187 | 1.00 | PNP (1.00) | PNPMTAP | |
| Galidesivir SCHEMBL16884051 | 1.00 | PNP (1.00) | PNPMTAP | |
| Galidesivir SCHEMBL29055146 | 1.00 | PNP (1.00) | PNPMTAP | |
| Galidesivir SCHEMBL23102311 | 1.00 | PNP (1.00) | PNPMTAP | |
| Galidesivir SCHEMBL15717852 | 1.00 | PNP (1.00) | PNPMTAP | |
| Galidesivir SCHEMBL25424734 | 1.00 | PNP (1.00) | PNPMTAP | |
| Galidesivir SCHEMBL12468816 | 1.00 | PNP (1.00) | PNPMTAP | |
| Galidesivir SCHEMBL17760735 | 1.00 | PNP (1.00) | PNPMTAP | |
| Galidesivir SCHEMBL15718263 | 1.00 | PNP (1.00) | PNPMTAP | |
| Galidesivir SCHEMBL4838048 | 0.99 | PNP (0.97) | PNPMTAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1406 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2026-05-28 | — | — | US | claimed |
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2026-05-21 | — | — | US | claimed |
| US-20260102422-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-04-16 | — | — | US | claimed |
| EP-4714452-A1 | METHODS FOR TREATING SARS COV-2 INFECTIONS | Gilead Sciences, Inc. (US) | 2026-03-25 | — | — | EP | claimed |
| EP-4704881-A2 | HUMORAL MODULATION IN VACCINATED AND VIRALLY INFECTED SUBJECTS WITH GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF) | Partner Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4704880-A1 | VIRAL INFECTION MODULATION IN VACCINATED SUBJECTS TREATED WITH GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF) | Partner Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| US-12551550-B2 | Compositions and vaccines for treating and/or preventing coronavirus variant infections and methods of using the same | ENGENEIC MOLECULAR DELIVERY PTY LTD (AU) | 2026-02-17 | — | — | US | claimed |
| EP-4680248-A1 | PRODUCTS OF MANUFACTURE AND THERAPEUTIC COMPOSITIONS FOR TREATING, AMELIORATING OR PREVENTING VIRAL INFECTIONS AND METHODS FOR MAKING AND USING THEM | Topelia Aust Limited (ACN 652 771 670) (AU) | 2026-01-21 | — | — | EP | claimed |
| EP-4676527-A2 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING CRIMEAN CONGO HEMORRHAGIC FEVER VIRUS | SVF Vaccines AB (SE) | 2026-01-14 | — | — | EP | claimed |
| EP-4673157-A2 | COMPOSITIONS FOR MODULATING GUT MICROFLORA POPULATIONS, TREATMENT OF DYSBIOSIS AND DISEASE PREVENTION, AND METHODS FOR MAKING AND USING SAME | Persephone Biosciences, Inc. (US) | 2026-01-07 | — | — | EP | claimed |
| WO-2022053993-A2 | TREATMENTS FOR SARS-COV-2 INFECTION (COVID-19) | MYLAN LABORATORIES LIMITED (IN) | 2022-03-17 | — | — | WO | claimed |
| WO-2022051650-A1 | HUMAN MONOCLONAL ANTIBODIES TO SARS-COV-2 AND USE THEREOF | THE UAB RESEARCH FOUNDATION (US) | 2022-03-10 | — | — | WO | claimed |
| EP-3963087-A1 | IDENTIFICATION AND ANALYSIS OF MICROBIAL SAMPLES BY RAPID INCUBATION AND NUCLEIC ACID ENRICHMENT | Illumina Inc (US) | 2022-03-09 | — | — | EP | claimed |
| WO-2022046642-A1 | COMPOUNDS AND COMPOSITIONS FOR DISRUPTING PROGRAMMED RIBOSOMAL FRAMESHIFTING | YALE UNIVERSITY (US) | 2022-03-03 | — | — | WO | claimed |
| WO-2022047311-A1 | COMPUTERIZED DECISION SUPPORT TOOL AND MEDICAL DEVICE FOR RESPIRATORY CONDITION MONITORING AND CARE | PFIZER INC. (US) | 2022-03-03 | — | — | WO | claimed |
| EP-3953361-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF COVID-19 | Pfizer Inc. (US) | 2022-02-16 | — | — | EP | claimed |
| WO-2022029334-A1 | COMBINATION THERAPIES FOR TREATING CORONAVIRUS INFECTION | GBIOTECH S.À.R.L. (CH) | 2022-02-10 | — | — | WO | claimed |
| US-20220031709-A1 | INHIBITION OF MICROSOMAL PROSTAGLANDIN E2 (PGE2) SYNTHASE-1 (MPGES-1) | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2022-02-03 | — | — | US | claimed |
| CN-113993518-A | Systemic isoxazoline repellents for the treatment or prevention of vector-transmitted and viral diseases | 塔苏斯制药有限公司 | 2022-01-28 | — | — | CN | claimed |
| CN-113952457-A | Application of termitimide or pharmaceutical composition containing termitimide in resisting coronavirus | 欣凯医药化工中间体（上海）有限公司 | 2022-01-21 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220031709-A1 | INHIBITION OF MICROSOMAL PROSTAGLANDIN E2 (PGE2) SYNTHASE-1 (MPGES-1) | PTGES, PTGS1, PTGES2 | PNP 724/4885MTAP 980/4885 |
| US-20260102422-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | SARS1, ITK, SLC43A1 | PNP 25/4885MTAP 23/4885 |
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | HAVCR2, NR1H4, NR1H3 | PNP 1440/4885MTAP 3703/4885 |
| US-12551550-B2 | Compositions and vaccines for treating and/or preventing coronavirus variant infections and methods of using the same | CACNG1, CACNG2, CACNG7 | PNP 2090/4885MTAP 1518/4885 |
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | ACE, MAVS, SARS1 | PNP 2061/4885MTAP 1906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.